Ignite Creation Date:
2024-05-06 @ 7:57 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06199882
Status:
SUSPENDED
Last Update Posted:
2024-01-10
First Post:
2023-12-29
Brief Title:
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Organization Data
Organization:
Zhejiang Cancer Hospital
Class:
OTHER
Study ID:
2023-383
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Zhejiang Cancer Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Liu luying
Responsible Party Title:
MD
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Zhejiang Cancer Hospital
Old Name:
None
Old Organization:
None